Will DD beat Q1 2026 adjusted EPS guidance of $0.48?

This is the first clean quarter for 'New DuPont' and management has every incentive to set a conservative guidance bar. The $0.48 EPS guide represents ~21% of the $2.275 full-year midpoint, which is a reasonable quarterly distribution. Management raised EBITDA guidance mid-year in FY2025, demonstrating conservative initial calibration. The $500M ASR reduces the share count, providing mechanical EPS accretion. Healthcare & Water Technologies momentum (mid-single-digit growth) and innovation pipeline (30% vitality) support Q1 execution. Insider activity with the entire management team as net buyers suggests confidence in near-term execution. High probability of beating the $0.48 bar.

Management has been conservative in guidance historically, and the first quarter of a transformed company is typically guided conservatively to ensure a positive first impression. The FY2025 pattern of raising guidance suggests management builds in a cushion. However, Q1 can be seasonally weaker for Building Technologies (construction), and the Aramis divestiture closing in Q1 creates accounting transition complexity. Separation-related costs could also create noise. The probability is high but not extreme, as one-time items could surprise.

Q1 2026 guidance at $0.48 is the management-set bar, and they have the best visibility into Q1 trends when setting this number. The $0.48 implies a Q1 EBITDA of ~$395M, which is ~22.7% of the full-year $1.74B target — a normal seasonal distribution. The key question is whether management built in the typical cushion above the minimum they need. Given the stakes of the first 'New DuPont' quarter, the cushion is likely meaningful. The main risk is an unexpected one-time charge (PFAS, separation costs) that creates adjusted EPS noise.

Management typically beats quarterly EPS guidance, especially when it's the first quarter of a major transformation. The $500M ASR provides share count reduction, and Healthcare growth momentum is stable. The main risk is separation-related items or Aramis divestiture accounting creating a miss. But on an 'adjusted' EPS basis, management controls what gets adjusted out. High probability of a beat.

Conservative Q1 guidance combined with stable Healthcare growth and buyback accretion supports a beat. However, Q1 is the quarter with the most separation-related complexity (Aramis closing, first full quarter post-Cunity). If adjusted EPS excludes these items, the underlying business should produce above $0.48. But if any operational surprise hits (construction worse than expected, unfavorable product mix, currency headwinds), the margin above $0.48 may be thin. Probability solidly above coin-flip but not extreme.

Strong insider buying is a positive signal for near-term execution. Management team collectively net buyers suggests confidence in the upcoming quarter. The $0.48 guide is likely set with a cushion given it's the debut quarter. Healthcare momentum and innovation pipeline (125 new products) provide revenue support. The question only asks whether EPS exceeds $0.48 — even a one-cent beat resolves YES. High probability.

First quarter of transformed company — management sets conservative bar. Buyback accretion helps. Healthcare momentum stable. High probability of beating $0.48.

Management guidance pattern is conservative. $0.48 guide likely has a cushion. Aramis transition creates some Q1 complexity but adjusted EPS should exclude one-time items. Above coin-flip probability.

Management insider buying, conservative guidance for debut quarter, buyback accretion, and stable Healthcare growth all support a Q1 EPS beat. Only a material surprise (PFAS charge, construction collapse) would cause a miss. High probability.